Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotics for gut microbiota and insulin resistance in obese men with metabolic syndrome
NL-OMON24894Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2011
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in insulin resistance (IR), obesity and cardiometabolic risk (CMR) comparing Amoxicillin with Vancomycin (2 arms). Primary endpoint: Change in fecal flora composition. Planned start Jan 2011; status: not yet recruiting.
02
Drugs
amoxicillinvancomycin
03
Conditions
insulin resistance (IR)obesitycardiometabolic risk (CMR)
Beyond the preview
Go deeper on NL-OMON24894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24894.